7 › 7.4 › 7.4.3
7.4.3 Phase 3 (pre-discharge and early post-discharge)
Pages 46–48 · open in PDF
Recommendations in this section
- Class ILevel CCareful evaluation before discharge is recommended in patients hospitalized for DHF to exclude persistent signs of congestion.
- Class ILevel B2An intensive strategy of rapid initiation and uptitration of FMT before discharge and during frequent follow-up visits in the first 6 weeks following an HFH is recommended to reduce the risk of HF rehospitalization or death.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 46 · PDF
tween different clinical phenotypes can exist. bConsultation with the Shock Team is recommended. cConsider in case of hypoxaemia. Consider when systolic blood pressure is >110 mmHg.
stabilized, to start/optimize long-term FMT to alter the course of the disease and improve patient outcomes. Decongestion is crucial and must be started and continued in phase 2 (Figure 13). Data from recent RCTs have demonstrated that initiating MRAs, SGLT2-Is, or ARNIs is feasible and safe in this phase of DHF.281,492,493 Much debate is ongoing on the optimal FMT initiation/optimization. It is clear that the traditional sequential approach is suboptimal and time-consuming. There is growing evidence that simultaneous implementation of FMT is more effective, safe, and associated with clinical benefit, thus this approach should be preferred. As no prospective RCT has been conducted comparing the different approaches to implementing FMT, no specific recommendation can be made regarding the number of drug classes to be introduced simultaneously or sequencing of the drugs. A more conservative approach may be reserved for specific (high-risk) groups of patients, such as patients with low eGFR, hypotension, and history of hyperkalaemia.
7.4.3. Phase 3 (pre-discharge and early post-discharge) This transition phase covers the last days of hospitalization and the first days/weeks after discharge.494 During this period, efforts should focus on reducing the risk of subsequent DHF/WHF
episodes, further optimizing FMT, and determining any indications for AMT and GDIT. The STRONG-HF trial demonstrated the safety and efficacy of an approach based on a rapid and intensive initiation and uptitration of FMT followed by close outpatient visits.311 This study has been criticized due to several limitations, including a highly selected population (based on NT-proBNP values and changes), the suboptimal medical treatment in the control arm and the lack of SGLT2-I use (lack of evidence and recommendations at the time when the study was conducted). Nevertheless, the trial showed that a strategy of fast uptitration after HFH is safe and feasible and therefore this approach is recommended. Safety indicators, including vital signs (blood pressure and heart rate) and laboratory tests (creatinine, potassium, and NT-proBNP) are helpful to guide uptitration.495 Residual congestion is associated with poor outcomes and a high risk of rehospitalization. Thus, pre-discharge assessment of residual congestion using clinical, laboratory, and imaging techniques is recommended (Figure 14).494 If not done earlier, the predischarge phase may also be used for iron supplementation in patients with iron deficiency (ID), based on the results of the AFFIRM-AHF trial (see Section 10.4).496 Finally, patients should be enrolled in disease management and rehabilitation programmes, educated, and guided in appropriate lifestyle adjustments.
Figure 13 Initial management of decompensated heart failure. HF, heart failure; MCS, mechanical circulatory support. aOverlap be-
Page 47 · PDF
∆≥
∆
Figure 14 Tools used for assessment of decongestion during the pre-discharge phase. All these tools are intended to be optional as no evidence from randomized controlled trials exists. BNP, B-type natriuretic peptide; CSI, congestion score index; EDT, E-wave deceleration time; IVC, inferior vena cava; LUS, lung ultrasound; LV, left ventricular; NP, natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TRV, tricuspid regurgitation velocity. aCongestion score = 0 denotes the absence of clinical congestion (absence of dyspnoea, orthopnoea, fatigue, rales, oedemas, jugular vein distension).497 Congestion score = 1–2 denotes mild congestion (slight or moderate dyspnoea, orthopnoea, fatigue, rales, oedemas, jugular vein distension).497 bThe CSI is a six-zone evaluation of a chest X-ray, with individual scores ranging from 0 to 3. A total score of 0 indicates all zones are clear (i.e. no congestion). cThe IVC is an optional tool to assess decongestion, although CAVA-ADHF showed no added benefit498.
Recommendations Careful evaluationc before discharge is recommended in patients hospitalized for DHF to exclude persistent signs of congestion. An intensive strategy of rapid initiation and uptitration of FMT before discharge and during frequent follow-up visits in the first 6 weeks following an HFH is recommended to reduce the risk of HF rehospitalization or death.311 DHF, decompensated heart failure; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization. a Class of recommendation. b Level of evidence. c Clinical evaluation, natriuretic peptide levels (Table 9), kidney function and electrolytes, imaging (see Figure 14).
Recommendation Table 8 — Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for decompensated heart failure (see Evidence Tables 59–67)
Page 48 · PDF
7.5. Treatment 7.5.1. Oxygen therapy Oxygen therapy is recommended in patients with hypoxaemia [oxygen saturation (SpO2) <90% or partial pressure of oxygen (PaO2) <60 mmHg]. Studies, including RCTs, have demonstrated that indiscriminate oxygen administration in non-hypoxaemic patients may be harmful.499–501
Non-invasive ventilation is recommended in patients with APO or CS and respiratory failure to improve oxygenation and reduce the need for intubation as shown by multiple trials and meta analyses.502,503 However, the increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease cardiac output and blood pressure and should therefore be used with caution in patients with reduced preload reserve and hypotension (i.e. decompensated right-sided HF). Endotracheal intubation is reserved for selected cases (see Recommendation Table 9).477
7.5.3. Diuretics (decongestion management) Intravenous loop diuretics remain the cornerstone of decongestion in DHF. In the DOSE-AHF trial, no difference in the primary efficacy outcome of patients’ symptom global assessment was shown with a high-dose regimen compared with a low-dose regimen of furosemide. There is no evidence indicating differential outcomes with i.v. bolus administration compared to continuous infusion or that one loop diuretic is superior to another.327,504 Patients naïve to diuretics usually respond well to 40 mg of i.v. furosemide or equivalent, whereas i.v. doses of two times the patient’s usual oral diuretic dose should be considered for patients who have been on loop diuretics as outpatients.505 Possible worsening kidney function should be evaluated in the context of diuretic response, because small and transient rises in serum creatinine during diuretic therapy are not associated with poor outcome if decongestion is achieved.506,507 Subsequent doses of loop diuretics during the initial days of hospitalization may be adjusted based on urinary sodium (uNa+) assessments, diuretic response, and the patient’s clinical status. A satisfactory diuretic response can be defined as a uNa+ content ≥70 mEq/L at 2 h or by a urine output ≥100 mL/h during the first 6 h (Figure 15). The PUSH-AHF trial showed that a strategy based on frequent clinical assessment, and uNa+-guided diuretic therapy led to higher natriuresis at 24 h vs standard of care.508 In the ENACT-HF open-label study, the uNa+-based approach also resulted in higher natriuresis and diuresis, as well as shorter hospital stay.509 No clinical trial has thus far showed benefit of uNa+-guided diuretic therapy on death or recurrent HFH. Intravenous diuretics should be continued until optimal decongestion is achieved; then, a switch to oral diuretics, if needed to maintain the volume status, is recommended. If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled and/or a non-loop diuretic added. (Figure 15). Two recent RCTs examined the role of non-loop diuretics for enhanced decongestion in DHF. In the ADVOR trial, patients
were randomized to i.v. acetazolamide (500 mg) or placebo added to i.v. loop diuretics. Treatment with acetazolamide resulted in a greater incidence of successful decongestion, defined as the absence of signs of volume overload within 3 days.510 In the CLOROTIC trial, oral hydrochlorothiazide (dose adjusted for eGFR) was compared with placebo in patients receiving i.v. furosemide.511 The treatment with hydrochlorothiazide resulted in more pronounced weight loss at 72 h but did not impact patientreported dyspnoea. Treatment with hydrochlorothiazide was associated with greater 24 h diuresis but also more likely worsened kidney function and hypokalaemia, warranting caution. Importantly, the study was prematurely halted due to slow recruitment. Both ADVOR and CLOROTIC did not show benefit of non-loop diuretics on hard endpoints. The pharmacotherapy of different diuretics and a practical guidance for their use in DHF is reported in Supplementary data online, Table S13. In patients with DHF, fluid intake should be less than urine output and fluid restriction may be appropriate in patients with hyponatraemia, based on individual assessment. Similarly, sodium intake should remain less than natriuresis. Implementing SGLT2-I and neurohormonal blockade, including MRA, can contribute to more effective and sustainable decongestion.512–514 Thus, it is imperative to consider early implementation and optimization of FMT in parallel to decongestion (Figure 15).
7.5.4. Decongestion management in the ambulatory setting In ambulatory patients with chronic HF showing signs of worsening, both i.v. diuretic administration and intensification of oral diuretic therapy can be considered. A practical guide for the outpatient management of WHF has been published, covering both ambulatory i.v. diuretics administered in a day-hospital setting and ‘hospital-at-home’ care models, including telehealth-enabled approaches.515–517 Diuretic sessions usually consist of a 3–6 h i.v. diuretic infusion with dosing based on the patient’s existing oral diuretic regimen. Close monitoring of kidney function, electrolyte levels, and treatment response, including measurements of urine output, uNa+, signs of clinical decongestion, biomarkers, and/or ultrasound findings, is essential.444,515,518 The new formulations of diuretics (e.g. subcutaneous) might be particularly useful for home treatment.519–521 Intensification of oral diuretic therapy may include: (i) initiating a loop diuretic in previously untreated individuals; (ii) increasing the total daily dose of a loop diuretic; or (iii) temporarily adding a diuretic with a different mechanism of action. Thiazide-like diuretics—particularly oral metolazone (2.5–5 mg)—can be used in patients with advanced HF who exhibit diuretic resistance, as part of a sequential nephron blockade approach, or in those with an eGFR <30 mL/min/1.73 m2. This strategy requires careful monitoring of eGFR and electrolytes. Patients with WHF that progresses to advanced HF are a key population for either outpatient i.v. diuretic treatment, whether in a day hospital or ‘hospital-at-home’ setting, or oral thiazidelike diuretics. Indeed, these patients often experience frequent hospitalizations and spend a substantial amount of time in hospital (‘frequent flyers’). Such patients require prompt evaluation for advanced HF treatments (see Section 8).
7.5.2. Ventilation support